Evidence map›Paper›PMID 42085612›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

N, S Co-Doped Carbon Quantum Dots-Riboflavin Composite Photosensitizers for Enhanced Iontophoresis-Assisted Corneal Cross-Linking.

Tinghong Xu, Yong Liu, Wenjing Zhang, Qiuruo Jiang, Yi Jin, Liangzheng Lin, Lumeng Wang, Zhanhao Gu, Mimi Lin, Shihao Chen

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tinghong XuSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yong LiuSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Wenjing ZhangSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Qiuruo JiangSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yi JinSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Liangzheng LinSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lumeng WangSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhanhao GuSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Mimi LinSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Shihao ChenSchool of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.ORCID https://orcid.org/0000-0001-7646-8003

Funding

Foundation of Wenzhou Science and Technology Bureau Y2020039Foundation of Wenzhou Science and Technology Bureau Y2020985Leading Goose" R&D Program of Zhejiang 2026C02A1184National Natural Science Foundation of China 31771020Youth Program of National Natural Science Foundation of China 81900909Youth Program of National Natural Science Foundation of China 82201247Zhejiang Province Medicine and Health Major Science and Technology Plan WKJ-ZJ-1829Zhejiang Provincial Natural Science Foundation of China LY20H120005
6 · The paper itself

Abstract

Iontophoresis-assisted corneal cross-linking (I-CXL) is an emerging transepithelial technique for treating keratoconus. I-CXL employs a small electric current to enhance the corneal penetration of riboflavin 5'-phosphate sodium (RF), avoiding the de-epithelialization side effects associated with conventional CXL (C-CXL). However, I-CXL is less effective than C-CXL due to insufficient RF surface charge hindering iontophoresis response and absorption efficiency, as well as inadequate reactive oxygen species (ROS) generation in the corneal stroma. This work reports the development of an innovative composite photosensitizer (NS-CQDs-RF), utilizing N, S co-doped carbon quantum dots (NS-CQDs) as nanocarriers, to overcome the bottlenecks facing I-CXL. Experimental results show that the as-synthesized NS-CQDs-RF composites exhibit a remarkable electric field response, enhanced RF corneal permeability, high ROS production efficiency, and excellent biocompatibility. Notably, I-CXL incorporating NS-CQDs-RF significantly improves corneal biomechanical stability, outperforming C-CXL while reducing total UVA irradiation energy without compromising efficacy. Density Functional Theory (DFT) calculations reveal that the optimized electronic structure and favorable energetics between NS-CQDs and RF drive efficient charge transfer, amplifying ROS generation. These findings highlight the superiority of the NS-CQDs-RF composite photosensitizers in I-CXL, offering a novel strategy for future keratoconus treatment.

Indexed as

Carbon Quantum DotsCorneaCorneal Cross-LinkingIontophoresisKeratoconusPhotosensitizing AgentsQuantum DotsRiboflavinAnimalsCarbonHumansReactive Oxygen SpeciesCarbonPhotosensitizing AgentsReactive Oxygen SpeciesRiboflavincarbon quantum dotscharge transfercorneal cross‐linkingiontophoresisNS‐CQDs‐RF composite photosensitizersreactive oxygen species

Identifiers

PMID42085612
PMCPMC13335933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.